Clinical trial
An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy
NCT02756364 is registered in ClinicalTrials.gov with Calithera Biosciences, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy
- Lead sponsor
- Calithera Biosciences, Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 28, 2016
- Completion date
- November 25, 2019
- Enrollment
- 141 (actual)
- Sites
- 53
Conditions
As the registry lists them; a condition with its own page is linked.